Resverlogix (STU:RFS) Days Payable: 0.00 (As of Mar. 2026)

What is Resverlogix Days Payable?

Resverlogix STU:RFS 39 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates STU:RFS with a GF Score™ of 39/100. The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, Resverlogix ranks worse than 141442.57% on this metric.

Resverlogix's average Accounts Payable for the three months ended in Mar. 2026 was €15.83 Mil. Resverlogix's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for Resverlogix's Days Payable or its related term are showing as below:

STU:RFS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Resverlogix's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Resverlogix Days Payable Related Terms

Resverlogix Days Payable Historical Data

* Premium members only.

The historical data trend for Resverlogix's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix Days Payable Chart

Resverlogix Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Resverlogix Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

STU:RFS vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Resverlogix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resverlogix Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Days Payable distribution charts can be found below:

* The bar in red indicates where Resverlogix's Days Payable falls into.

Save Embed

39GF Score

Resverlogix Corp STU:RFS

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Resverlogix Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Resverlogix's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (15.282	+	15.529)	/	2 )	/	0	*	365
=	15.4055					/	0	*	365
=	N/A

Resverlogix's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (15.529	+	16.136)	/	2 )	/	0	*	365 / 4
=	15.8325					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Resverlogix (STU:RFS) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Resverlogix and its competitors. According to the industry distribution chart, Resverlogix ranks #999999 out of 707 companies in the Biotechnology industry.

Is Resverlogix's Days Payable too high?

Resverlogix's current Days Payable is 0.00. Based on the distribution chart, Resverlogix ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Resverlogix has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.

How does Resverlogix's Days Payable compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Resverlogix ranks #999999 out of 707 companies for Days Payable. This places Resverlogix in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Resverlogix and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resverlogix's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Resverlogix stock overvalued right now?

Resverlogix (STU:RFS) has a current Days Payable of 0.00. The current Days Payable is 0.00. Resverlogix's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Resverlogix (STU:RFS), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resverlogix Business Description

Industry Healthcare Biotechnology

Comparable Companies TSXV:ARCH XCNQ:LOBE TSXV:GSD TSXV:TTI TSX:MDNA TSX:BCT TSX:MBX XCNQ:MDMA TSXV:MIR NEOE:BMND VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges RVXCF:USA RVX:Canada

Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1

Website https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

39GF Score

Get the complete analysis for STU:RFS

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05

Price

View STU:RFS Analysis

See Days Payable data for all stocks →